CHAPEL HILL, N.C., Aug. 15, 2014 /PRNewswire/ -- Managing all the aspects of successfully launching a new oncology product is a daunting endeavor that often falls to the Global Strategic Marketing (GSM) function. As the oncology market continues to be a rapid growth area for the biopharmaceutical industry, leaders must continually assess their budgets, investment strategies, staffing, structure and scope of services.
According to recent research Global Strategic Marketing organizations are shifting their budgets to better fit their current needs. Budget increases are anticipated by as much as 73% of benchmark participants for activities supporting the Oncology pipeline. Few participants project any decreases in their budgets for this area.
The related report, "Oncology Global Strategic Marketing: Benchmarking Budget Levels & Service Scope," will help GSM leaders in oncology to better evaluate and improve their global strategic marketing programs. The study will allow leaders to understand the investment levels, marketing activities, timing, and structures needed to successfully steer products and pipeline programs through the complex oncology marketplace.
The 75-page study provides current benchmarks, such as:
- GSM staffing benchmarks by role, by development phase, by number of oncology programs and per $100M in oncology sales
- Outsourced and in-house labor dedicated to traditional and emerging markets
- GSM organizational structure
- Role of the GSM function for activities such as market intelligence, marketing, advocacy and KOL management
- Spending benchmarks around key GSM activities within marketing, market intelligence and advocacy
- Oncology GSM spending by phase of clinical development
The study engaged GSM leaders supporting Oncology organizations at 17 companies. The study included both large, established and small, emerging Oncology companies to provide the broadest insights. Data is presented for large and emerging company segments throughout the report.
To access the full report, or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1307.htm
For more information on other recent primary research studies, contact us at 919.403.0251. For related research, visit our Best Practices, LLC website at http://www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
SOURCE Best Practices, LLC